Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status.

Related Articles

Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status.

Oncotarget. 2018 Mar 06;9(18):14738-14740

Authors: Chauhan A, Arnold SM, Kolesar J, Thomas HE, Evers M, Anthony L

Abstract
Introduction: Large cell neuroendocrine carcinomas (LCNEC) are a group of rare high grade neuroendocrine tumors that often behave clinically like small cell carcinoma (SCLC) and are treated as such. No major advancement in the management of these tumors has occurred in the last 30 years.
Methods: We present a case series of three cases from Markey Cancer center along with a review of 13 published cases in the literature wherein immune-checkpoint inhibitors were utilized in the management of LCNEC.
Results: Immune-checkpoint inhibitors might have clinical activity in LCNEC.
Conclusion: Role of immune-checkpoint inhibitors should be explored in prospective LCNEC clinical trials. We summarize current evidence regarding use of immune checkpoint inhibitors in the treatment of LCNEC.

PMID: 29581877 [PubMed]

https://ift.tt/2I6QjdF